Treace Announces Participation in Two Upcoming Investor Conferences

Rhea-AI Summary

Treace Medical Concepts (Nasdaq: TMCI) will participate in two investor conferences on November 10–11, 2025. The company will appear at the UBS Global Healthcare Conference on Monday, November 10, 2025, with a fireside chat at 11:45 AM ET, and at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025.

A live webcast and replay of the UBS fireside chat will be available on the company’s Investor Relations website at https://investors.treace.com/. Treace routinely posts investor‑important information in the Investor Relations section at www.treace.com and encourages investors to check the site regularly.

News Market Reaction

-28.33% 3.2x vol

11 alerts

-28.33% News Effect

-11.1% Trough in 3 hr 2 min

-$156M Valuation Impact

$394M Market Cap

3.2x Rel. Volume

On the day this news was published, TMCI declined 28.33%, reflecting a significant negative market reaction. Argus tracked a trough of -11.1% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $156M from the company's valuation, bringing the market cap to $394M at that time. Trading volume was very high at 3.2x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

PONTE VEDRA, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will participate in the following upcoming investor conferences.

• The UBS Global Healthcare Conference on Monday, November 10, 2025, with a fireside chat at 11:45 am ET; and
• The Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025

A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.treace.com/.

Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty^® 3D Bunion Correction^® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion surgeons and address the four classes of bunions, Treace introduced its Adductoplasty^® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. Treace continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate^® Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty^®, Adductoplasty^® and SpeedMTP™ procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.

To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.

Contacts:

Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net 
(904) 373-5940

Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net 

FAQ

When will Treace (TMCI) present at the UBS Global Healthcare Conference?

Treace will present at the UBS Global Healthcare Conference on November 10, 2025 with a fireside chat at 11:45 AM ET.

Will Treace (TMCI) webcast the UBS fireside chat on November 10, 2025?

Yes. A live webcast and replay of the UBS fireside chat will be available on Treace’s Investor Relations website at https://investors.treace.com/.

When is Treace (TMCI) scheduled to participate at the Stifel 2025 Healthcare Conference?

Treace is scheduled to participate at the Stifel 2025 Healthcare Conference on November 11, 2025.

Where can investors find Treace (TMCI) investor updates and webcast replays?

Investors can find updates and webcast replays on Treace’s Investor Relations website at https://investors.treace.com/ and the company site at www.treace.com.

What topics will Treace (TMCI) cover at the November 2025 investor conferences?

The company will discuss recent developments and outlook in a fireside chat and conference sessions; specifics will be available via the webcast and investor website.